文献速递甲状腺疾病

亚临床甲状腺乳头状癌患病率的年龄分布:尸检研究的Meta分析

Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该Meta分析纳入16项尸检研究(n=6286例尸检),评估亚临床甲状腺乳头状癌(PTC)患病率随年龄的变化。全腺体检查的汇总患病率为12.9%(95%CI 7.8-16.8),部分腺体检查为4.6%(2.5-6.6)。各年龄组患病率相近,年龄组每增加一级的OR为1.06(0.92-1.2,P=.37),提示亚临床PTC患病率在整个生命周期中保持稳定。

要点

  • 全腺体检查的亚临床PTC汇总患病率为12.9%(95%CI 7.8-16.8)。
  • 部分腺体检查的汇总患病率为4.6%(95%CI 2.5-6.6)。
  • 年龄组每增加一级的OR为1.06(0.92-1.2,P=.37),患病率随年龄无显著变化。

核心结论

  • 该Meta分析显示亚临床PTC的患病率在整个生命周期中保持稳定。
  • 中年人群的亚临床PTC患病率并不更高,与该年龄组观察到的较高发病率形成对比。

研究设计与样本

  • 检索PubMed、Embase和Web of Science数据库自建库至2021年5月的研究。
  • 纳入16项报告尸检发现PTC患病率且提供年龄特异性数据的研究,共6286例尸检。
  • 两名研究者提取选定年龄组中检测到的亚临床PTC数量及检查范围,并使用质量评估工具评估偏倚。
  • 采用带随机截距的逻辑回归模型合并年龄特异性亚临床PTC患病率估计值。

主要发现

  • 全腺体检查的亚临床PTC汇总患病率为12.9%(95%CI 7.8-16.8),部分腺体检查为4.6%(95%CI 2.5-6.6)。
  • 年龄特异性患病率:≤40岁为11.5%(95%CI 6.8-16.1),41-60岁为12.1%(95%CI 7.6-16.5),61-80岁为12.7%(95%CI 8-17.5),81岁及以上为13.4%(95%CI 7.9-18.9)。
  • 性别不影响年龄特异性患病率,任何年龄组中男性和女性之间的患病率均无差异。
  • 回归模型中,年龄组每增加一级的OR为1.06(95%CI 0.92-1.2,P=.37)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It is not known how underlying subclinical papillary thyroid cancer (PTC) differs by age. This meta-analysis of autopsy studies investigates how subclinical PTC prevalence changes over the lifetime. METHODS: We searched PubMed, Embase, and Web of Science databases from inception to May 2021 for studies that reported the prevalence of PTC found at autopsy. Two investigators extracted the number of subclinical PTCs detected in selected age groups and extent of examination. A quality assessment tool was used to assess bias. Logistic regression models with random intercepts were used to pool the age-specific subclinical PTC prevalence estimates. RESULTS: Of 1773 studies screened, 16 studies with age-specific data met the inclusion criteria (n = 6286 autopsies). The pooled subclinical PTC prevalence was 12.9% (95% CI 7.8-16.8) in whole gland and 4.6% (2.5- 6.6) in partial gland examination. Age-specific prevalence estimates were ≤40 years, 11.5% (6.8-16.1); 41-60 years, 12.1% (7.6-16.5); 61-80 years, 12.7% (8-17.5); and 81+ years, 13.4% (7.9-18.9). Sex did not affect age-specific prevalence and there was no difference in prevalence between men and women in any age group. In the regression model, the OR of prevalence increasing by age group was 1.06 (0.92-1.2, P = .37). CONCLUSION: This meta-analysis shows the prevalence of subclinical PTC is stable across the lifespan. There is not a higher subclinical PTC prevalence in middle age, in contrast to higher observed incidence rates in this age group. These findings offer unique insights into the prevalence of subclinical PTC and its relationship to age.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Arroyo N, Bell KJL, Hsiao V, et al. Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies. J Clin Endocrinol Metab. 2022. PMID: 35947867. doi:10.1210/clinem/dgac468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。